Silo Pharma Announces Share Buyback Program
MWN-AI** Summary
Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company that integrates traditional therapies with psychedelic research, has announced a new share buyback program authorized by its board of directors. The program allows the company to repurchase up to $1 million of its common stock, reflecting a commitment to enhance shareholder value in light of current market conditions. As of November 13, 2025, Silo Pharma reported having 13,318,273 shares outstanding, providing a basis for its planned buyback efforts.
The company has the flexibility to execute these purchases through a variety of mechanisms, including open market transactions and privately negotiated deals, ensuring compliance with U.S. Securities and Exchange Commission regulations. The Chief Executive Officer, Eric Weisblum, expressed confidence that the buyback program would effectively leverage market dynamics to create additional value for shareholders.
The execution of the buyback will be periodic and dependent on market conditions and regulatory limitations, with no obligation to repurchase a specified number of shares. Silo Pharma's strategic focus is on underserved health conditions, particularly stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its portfolio includes potential therapies such as SPC-15 for PTSD and SP-26 for fibromyalgia, reflecting its innovative approach in the biopharmaceutical sector.
In light of its developmental stage, Silo Pharma emphasizes the inherent risks associated with forward-looking statements regarding the company’s future prospects, prompting caution among investors. Despite the uncertainties, the company’s commitment to shareholder value and therapeutic innovation position it as a noteworthy entity in the biopharmaceutical landscape. For more information, investors can contact Silo Pharma at (800) 705-0120 or via email at investors@silopharma.com.
MWN-AI** Analysis
Silo Pharma, Inc. (Nasdaq: SILO) has announced a share buyback program of up to $1 million, a strategic move that signals confidence in the company’s future and aims to enhance shareholder value. This initiative comes at a time when the market may be undervaluing the company, particularly given its focus on innovative treatments for psychiatric disorders and chronic pain, areas with significant unmet needs.
From a market perspective, buyback programs often act as a positive signal to investors, suggesting that the company's leadership believes the stock is undervalued. With approximately 13.3 million shares outstanding, the buyback has the potential to reduce the float, consequently increasing earnings per share (EPS) and potentially buoying the stock price. This could attract both institutional and retail investors, as a reduced share count typically indicates stronger performance metrics on a per-share basis.
Moreover, Silo's engagement in cutting-edge biopharmaceutical research coupled with its plans to address CNS diseases positions it well to capitalize on the growing interest in such therapies. As the psychedelic research landscape evolves, Silo's initiatives, particularly in collaboration with renowned universities, could provide it with a competitive edge. The company’s potential to innovate while returning capital to shareholders may help solidify its reputation in the market.
However, investors should approach this news with caution. The buyback program is contingent on market conditions and may be suspended at the company's discretion. Additionally, the biopharmaceutical sector is inherently volatile, and success is not guaranteed, particularly in developmental-stage companies like Silo. Thus, while the buyback serves as an optimistic marker, potential investors should weigh this against the risks attached to a company still in the early stages of its product development pipeline.
In conclusion, while Silo Pharma’s buyback program can be viewed as a positive development, investors should conduct thorough due diligence and consider both market trends and the inherent risks of biopharmaceutical investments before making decisions on their positions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The Company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as reported in its Quarterly Report for the period ended September 30, 2025.
“We believe that the current capital market conditions should allow us to capture additional value for all shareholders through this measured buyback program. Our Board of Directors and executive management team remain committed to delivering value to our shareholders,” said Eric Weisblum, Chief Executive Officer.
The timing, number of shares repurchased, and prices paid for the stock under this program will depend on market conditions and corporate and regulatory limitations, including blackout period restrictions. The repurchase program does not obligate the Company to acquire any specific number of shares, and it may be suspended or discontinued at the Company's discretion.
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
investors@silopharma.com
FAQ**
How does Silo Pharma Inc. SILO plan to allocate the $1 million budget for its share repurchase program in light of the current market conditions?
What specific metrics will Silo Pharma Inc. SILO use to evaluate the success of its buyback program and its impact on shareholder value?
Can Silo Pharma Inc. SILO provide insights into how the implementation of the share repurchase program aligns with its long-term strategic goals and therapeutic focus?
In what ways does Silo Pharma Inc. SILO plan to communicate any updates regarding the buyback program to its investors and stakeholders?
**MWN-AI FAQ is based on asking OpenAI questions about Silo Pharma Inc. (NASDAQ: SILO).
NASDAQ: SILO
SILO Trading
7.5% G/L:
$0.361 Last:
138,292 Volume:
$0.35 Open:
